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1238Objective: We sought to evaluate the results of surgical repair and determine predictors for the late outcome of
congenital mitral valve dysplasia.
Methods: Preoperative, operative and postoperative data were obtained from an institutional database; follow-up
data came from regular clinical evaluation at our institution or elsewhere. Patients were divided into isolated and
complex cases according to the complexity of associated lesions.
Results: Between 1972 and 2008, 93 patients (43 male and 50 female patients) underwent mitral repair (median,
4.5 years; range, 0.16–19.8 years). Predominant mitral regurgitation was present in 52%. Associated cardiac anom-
alies were present in 72%. Sixty-one patients were in the complex group. All patients underwent successful mitral
repair. Surgical repair was tailored to the patient’s valve anatomy. Early death was 7.5%. The postoperative course
was uneventful in 86% of patients. At a mean follow-up of 10.3 years (median, 8.4 years; completeness, 94%), late
mortality is 8% (7 patients). Twelve patients underwent mitral reintervention (11 replacements and 1 repair).
Among the 80 survivors, 82.5% were in New York Heart Association class I or II, and 61.2% had some degree
of persistent mitral regurgitation or stenosis, despite stable hemodynamics. Stenosis is a statistically significant
risk factor for surgical intervention at less than 1 year of age and is related to higher overall mortality and incidence
of late cardiac failure and mitral dysfunction; parachute mitral valve is related to higher mortality and morbidity.
Conclusions: Mitral valve repair shows acceptable early mortality and reoperation rates. Mitral malformations in
the complex group are related to a significantly higher risk of reoperation on the mitral valve. Parachute mitral
valve is associated with a higher rate of early mortality. (J Thorac Cardiovasc Surg 2010;140:1238-44)Earn CME credits at
http://cme.ctsnetjournals.org
Congenital mitral valve (CMV) dysplasia is a relatively rare
and highly complex cardiac malformation that presents with
a wide variety of morphologic abnormalities, as well as
a high incidence of associated intracardiac anomalies.1-3
Surgical repair of CMV anomalies has represented a major
therapeutic challenge, the approach to which has
significantly evolved, as reported by various authors.4-8
Valve repair rather than replacement for CMV dysplasia
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The Journal of Thoracic and Cardiovascular Surmostly because of the untoward deleterious effects of
prosthetic valve replacement, particularly in small children.
We report our 36-year experience with surgical treatment
of CMV disease, with particular attention to the long-term
performance of the reconstructed mitral valve (MV), as
well as to the effects of associated intracardiac lesions,
which might influence long-term results after repair.MATERIALS AND METHODS
All consecutive patients affected by CMV dysplasia referred to our cen-
ter and scheduled for surgical repair between October 1972 and January
2008 were included. Exclusion criteria were the association with atrioven-
tricular septal defects, hypoplastic left heart syndrome, or other types of
functional single-ventricle anomalies and MV prosthetic replacement as
the first operation. According to Carpentier’s physiopathological classifica-
tion,9 patients were divided into 2 groups: group I, patients with CMV re-
gurgitation or prevalent mitral regurgitation (MR); group II, patients with
MV stenosis (MS) or prevalent MS. To evaluate the clinical importance
of the associated cardiac abnormalities, the patients were further arbitrarily
subdivided into 2 subgroups according to the severity of the associated in-
tracardiac anomalies rather than the anatomic severity of the dysplastic MV
itself: isolated group, when any anatomic type of CMV dysplasia was iso-
lated or in association with ‘‘simple’’ intracardiac lesions, such as an atrial
septal defect or a patent ductus arteriosus; complex group, when any type of
CMV dysplasia (regardless for its anatomopathological severity) coexisted
with other malformations, such as aortic isthmic coarctation, aortic or sub-
aortic stenosis, or ventricular septal defects.gery c December 2010
Abbreviations and Acronyms
CI ¼ confidence interval
CMV ¼ congenital mitral valve
MR ¼ mitral regurgitation
MV ¼ mitral valve
NYHA ¼ New York Heart Association
OR ¼ odds ratio
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DReview of medical records and computerized hospital data was approved
by our University Hospital Committee on Clinical Investigation, and the
procedures followed were in accordance with institutional guidelines for ret-
rospective record review and protection of patient confidentiality. The need
for patient consent was waived.
Follow-up was based on clinical and instrumental data derived from
records of the outpatient clinic of the Department of Pediatrics of the Uni-
versity of Padua, where most patients were clinically evaluated on a regular
basis. However, those patients who were followed elsewhere were con-
tacted by telephone, and clinical and instrumental data were provided by
the referring cardiologist after obtaining consent.
Early and late-term outcomes were evaluated according to early (within
30 days or in the hospital) and late mortality, freedom from reoperation (ei-
ther any cardiac operation or specifically redo operation on the MV), and
clinical conditions, expressed as New York Heart Association (NYHA)
functional class (I–IV), need for chronic cardiac medications, presence or
absence of sinus rhythm, and hemodynamically significant residual valve
defects. Hemodynamic significance was as follows: MR if flow conver-
gence region10 was greater than 100 mL $ min1 $ m2 and MS if transmitral
velocity was greater than 1.3 m/s.
Descriptive and multivariate analyses were applied to the outcomes
(mortality, need for drug treatment, reoperation, need for surgical interven-
tion on the MV before 1 year of age, hemodynamic stability, and sinus
rhythm) to establish the effect of the following risk factors: age, sex, com-
plex case, MV stenosis, parachute MV, need for surgical intervention on the
MV before 1 year of age, and cleft MV. Age is expressed as a continuous
variable, with median, mean, and standard deviation. The remaining vari-
ables are dichotomous. The relationship between every outcome and a single
dichotomous risk factor was calculated by using the Fisher exact test when
frequencies were less than 5 and by using the c2 test when expected frequen-
cies were greater than 5. The statistical significance was assumed by using
a cutoff threshold of a P value of .05. Moreover, every outcome was related
to several risk factors by means of a logistic regression model, in which the
significant incremental (odds ratio [OR]>1) or decremental (OR<1) risk
factors were identified by means of a stepwise selection method.
Because of the very long period of recruitment, time was considered an
explanatory variable. In this way the multivariate analysis provides the im-
portance of the risk factors’ net of a potential time effect. After several tests,
the most efficient use of the time variable was as a dichotomous one: a first
period from 1972 to 1984 and a second period from 1985 to 2008.
Kaplan–Meier analysis was used to evaluate freedom from death and re-
operation for different groups (MS vs MR and isolated vs complex) and dif-
ferent preoperative conditions, such as mitral anatomy.
Statistical analyses were performed with SPSS (SPSS, Inc, Chicago, Ill)
and SAS (SAS Stat 9.1; SAS Institute, Inc, Cary, NC) statistical software.RESULTS
Between October 1972 and January 2008, 96 consecutive
patients affected by CMV dysplasia underwent surgical inter-
vention at our institution. Among these, 3 patients in our earlyThe Journal of Thoracic and Carexperience (before January 1985) underwent MV replacement
with a prosthesis as a primary treatment because of an initially
different surgical philosophy in approaching severe CMV
malformations at that time. Thus 93 patients were treated
with primary CMV repair and are the object of this study.
The median age at the time of the operation was 4.5 years
(mean, 5.8  4.9 years); 13 (14%) patients were younger
than 12 months. Since January 1991, all patients were given
diagnoses based on exclusive, preoperative, routine
2-dimensional echocardiographic examination, during
which cardiac catheterization was performed as a primary
or complementary instrument for diagnosis before 1991, ac-
counting for 44.1% of the diagnoses.
Twenty (26.8%) patients presented clinically with dyspnea
and 10 with failure to thrive, whereas 5 patients were admitted
on an emergency basis in cardiogenic shock on mechanical
ventilation and inotropic drugs. The remaining patients had
either mild or no symptoms. The cardiothoracic ratio on plain
radiographic analysis was greater than 0.5 in 52 (56%) pa-
tients. According to Carpentier’s classification,9 48 (51.6%)
patients presented with MR or prevalent MR, whereas the re-
maining 45 (48.4%) had MS or prevalent MS (Table 1).9 Pre-
operative pulmonary mean arterial pressure was available in
22 patients of those submitted to cardiac catheterization,
and it was 37 mm Hg (range, 16–60 mm Hg).
Associated cardiac anomalies were found in 67 (72%)
cases. According to the abovementioned subdivision, 32
(34.4%) patients were in the isolated group, whereas 61
(65.6%) were in the complex group. Thirty patients had
undergone a previous cardiac procedure, either surgical or
interventional (Table 2).
All patients were submitted to successful MV repair.
Various surgical techniques were used, as previously
reported,4,5 according to the surgeon’s preference, the
different cardiac pathological anatomy, and the different
period. As a general rule, each operation was tailored to
the peculiar anatomy of each type of CMV dysplasia.
Surgical techniques and data are summarized in Table 3.
Significant complications occurred in 14 (15%) patients
and are summarized in Table 4. Early mortality was 7.5%
(7 patients). Main causes of death were low cardiac output
syndrome in 4 patients, hemorrhagic shock in 2 patients,
and mediastinitis in 1 patient (Table 4). Five (71%) patients
died before January 1984. There were only 2 early deaths
among 68 subsequent consecutive patients undergoing oper-
ations after 1984 and no deaths since March 2002.
Of the 13 patients who required surgical treatment within
the first year of life, 86% (11 patients) had MS, and 86%
(11 patients) were in the complex group. There were 2 early
deaths (15.4%).
Follow-up
Of the 86 surviving patients, 6 live abroad and were lost to
follow-up. Late follow-up was available for the remainingdiovascular Surgery c Volume 140, Number 6 1239
TABLE 1. Types of CMV dysplasia according to Carpentier’s
classification9
MV malformations No. of patients
MV regurgitation (or prevalent) 48
Type I (normal leaflet motion) 32
Annular dilatation 12
Cleft anterior leaflet 18
Leaflet defect 2
Type II (leaflet prolapse) 9
Elongated chordae 9
Type III (restricted leaflet motion) 7
Type A (normal papillary muscles)
Papillary muscles commissure fusion 1
Short chordae 2
Type B (abnormal papillary muscles)
Parachute MV 2
Hammock MV 2
MV stenosis (or prevalent) 45
Type A (normal papillary muscles) 24
Papillary muscle commissure fusion 14
Supravalvular membrane 7
Double-orifice MV 3
Type B (abnormal papillary muscles) 21
Parachute MV 10
Hammock MV 4
Shone complex 5
Arcade MV 2
Total 93
CMV, Congenital mitral valve; MV, mitral valve.
TABLE 3. Surgical techniques used to achieve mitral valve repair
Technique No. of patients
Papillary muscle splitting 35
Cleft closure 21
Annuloplasty (Kaye, Paneth) 20
Supravalvular ring excision 16
Commissurotomy 15
Chordal shortening 9
Ring annuloplasty 6
Commissuroplasty 4
Accessory orifice closure 2
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(median, 8.4 years; range, 0.5–36.4 years). Late mortality
occurred in 7 (8%) patients; death was cardiac related in 6
patients and was caused by chronic congestive heart failure
in 5 patients and prosthetic valve thrombosis in 1 patient
who had required late prosthetic replacement of the initially
preserved MV.
Sixteen (18.4%) patients required reoperations. These
were on the MV in 12 patients: 7 had residual MS, and 5
had residual MR. The mean interval between the first proce-
dure and reoperation was 4.9 years (range, 2.2 months toTABLE 2. List of patients with associated cardiac anomalies in the
complex group and those in whom repair of cardiac anomaly was
performed before MV repair
Cardiac anomaly No. of patients
Patients with previous
surgical intervention
Subaortic stenosis 31 7
VSD 23 0
Aortic coarctation 19 19
Aortic regurgitation 4 0
Pulmonary stenosis 3 2
Abnormal LAD origin 2 0
Other 11 2*
MV, Mitral valve; VSD, ventricular septal defect; LAD, left anterior descending. *Two
patients had patent ductus arteriosus closure at birth.
1240 The Journal of Thoracic and Cardiovascular Sur19.2 years). MV replacement was necessary in 11 patients
(a mechanical prosthesis in 10 and a biological valve in 1 fe-
male patient). In 1 patient with a typical Shone’s complex
with a parachute MV (complex group), a successful MV re-
repair (papillary muscle resplitting procedure) was possible
12.4 years after the initial operation because of significant re-
sidual MS. The remaining 4 redo procedures included a per-
manent pacemaker implantation for intermittent complete
atrioventricular block in 2 cases (0.03 and 22.6 months after
MV repair, respectively), a modified Konno operation 36.9
months postoperatively in 1 patient, and a subaortic ridge re-
section 39.4 months after the initial repair in another patient.
At a mean follow-up of 10.3 9.3 years, 65 (81.25%) pa-
tients are in NYHA class I or II, and 15 (18.75%) patients
are symptomatic with fatigue and reduced effort tolerance
and are therefore in NYHA class III or IV. Three of the latter
are under evaluation for elective reoperation (1 patient with
MS caused by an MV arcade, 1 with a biological prosthesis
implanted 19 years after CMV repair for a parachute MV,
and 1 with MS in a Shone’s complex). Seventy (87.5%) pa-
tients are in stable sinus rhythm, and 10 (12.5%) patients
have cardiac arrhythmias: 4 required a pacemaker for post-
operative atrioventricular conduction block, 4 have chronic
atrial fibrillation, and 2 have ectopic atrial rhythm.
Thirty-four (42.5%) patients require oral medications (an-
giotensin-converting enzyme inhibitors, diuretics, and war-
farin). Two-dimensional echocardiographic analysis at the
time of last follow-up has shown absent or minimal residual
MV dysfunction in 30 (38.5%) patients, whereas 50 (62.5%)
patients presented with a hemodynamically significantTABLE 4. List of patients with early postoperative complications that
led to early death
Complications No. of patients Exitus
LCO syndrome 4 4
Bleeding 4 2
Complete AV block 2 0
Pericardial effusion 1 0
Pleural effusion 1 0
Mediastinitis/septic shock 1 1
Postpericardiotomy syndrome 1 0
LCO, Low cardiac output; AV, atrioventricular.
gery c December 2010
FIGURE 1. Kaplan–Meier analysis shows that overall survival is 75% at 36 years.
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MR in the remaining 22 patients). Among those 11 survivors
who had undergone operations within the first year of life, 2
died late, accounting for an overall mortality in this small
subgroup of 30.8%. Reoperations were required in 27.3%.Statistical Analysis
Survival curves according to Kaplan–Meier analysis are
shown in Figures 1 to 3. Overall survival is 75% at 36
years (Figure 1). Freedom from reoperation on the MV is
77% at 36 years (Figure 2). The survival estimate for pa-
tients with MS is significantly lower than for patients withFIGURE 2. Kaplan–Meier analysis shows that freedom fr
The Journal of Thoracic and CarMR (P ¼ .021; OR, 4.698; Figure 3). Although survival es-
timates for patients with complex lesions appear to be lower
than in the isolated group, this proved to be not statistically
significant (P ¼ .21).
The descriptive analysis of risk factors shows the following:
 Male sex has a greater incidence of complex MV disease
(OR, 6.167; 95% confidence interval [CI], 2.167–17.542)
and MS (OR, 2.429; 95% CI, 1.026–5.748). In addition,
complex CMV disease and MS are strictly related
(c2 ¼ 4.93, P ¼ .0263).
 Concerning freedom from reintervention on the MV,
there was no statistically significant difference betweenom reoperation on the mitral valve is 77% at 36 years.
diovascular Surgery c Volume 140, Number 6 1241
FIGURE 3. Kaplan–Meier analysis shows that survival estimates for patients with mitral stenosis are significantly lower than for patients with mitral regur-
gitation (P ¼ .021; OR, 4.698).
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the MS group was at higher risk for late heart failure
(P¼ .026; OR, 3.870) and persistence of MV dysfunction
(defined as above: P ¼ .049; OR, 2.545).
 At follow-up, a parachute MV was significantly associ-
ated with a worse late clinical outcome (NYHA class III
and IV: P ¼ .037; OR, 5.545).
 Persistence of MV dysfunction was significantly in-
creased in those patients who had undergone CMV repair
within their first year of life (P ¼ .046).
Logistic regression analysis is shown in Table 5 and
demonstrates the following:
 MS proved to be a significant risk factor for early opera-
tion (within the first year of life: OR, 7.219; 95% CI,
1.494–34.88) but not for early or late death (OR, 6.973;
95% CI, 0.0802–80.6). Even if stenosis, considered
alone, is significant for death, it is no longer significant
at multivariate analysis, when many risk factors are con-
sidered at the same time. In this case parachute MV and
age are significant risk factors for early death, and they
are related with MS. When parachute MV and age areTABLE 5. Significant risk factors for several outcomes at logistic regressi
Outcomes Complex MV (OR) MV stenosis
Any adverse outcome 3.173 2.520
Early death –
Late death – 6.973
Preoperative medical therapy – –
Reoperation on MV – –
Operation on MV before 1 y of age – 7.219
Heart failure at follow-up – –
Arrhythmias – –
Variables significant at a level of .05<P< .1 are shown in italics. MV, Mitral valve; OR,
1242 The Journal of Thoracic and Cardiovascular Surconsidered in the analysis, MS turns out to have a less sig-
nificant effect on survival because patients with MS are
younger (P ¼ .0015) and have parachute MV (P ¼ .026).
 There was no significant difference between the isolated
and complex groups in early need for surgical interven-
tion or early and late mortality; however, the complex
group had a significantly higher risk for presenting with
unsatisfactory outcomes at follow-up (OR, 3.173; 95%
CI, 1.158–8.693).
 A parachute MV is an important risk factor for late reop-
eration on the MV (OR, 6.817; 95% CI, 1.578–29.457),
late heart failure (OR, 6.1; 95% CI, 1.309–28.420), and
loss of sinus rhythm (OR, 6.377; 95% CI, 1.107–
36.737). Also, residual stenosis of a parachute MV was
a more common finding (P ¼ .0264, Fisher exact test).
Finally, because our time frame of follow-up evaluation
was quite wide, our statistical analysis was aimed at identify-
ing the effect of time on early and late outcomes. As a result,
we were able to demonstrate increased risk factors (18- and
4.7-fold, respectively) for early death and loss of sinus rhythm
in those patients who underwent surgical repair before 1984.on analysis
Variables
(OR) Parachute MV (OR) Before 1984 (OR) Age, y (OR)
– – –
7.122 18.40 0.636
– – –
4.889 – –
6.817 – –
– – –
6.100 – –
6.377 4.744 –
odd ratio.
gery c December 2010
Stellin et al Congenital Heart Disease
C
H
DDISCUSSION
This report reviews our 36-year experience with surgical
management of CMV dysplasia. To the best of our knowl-
edge, this series represents the largest cohort of patients
who underwent MV repair for MV dysplasia, including
long-term follow-up data.
This rare entity, which often coexists with other complex
lesions of the left heart, continues to present a significant
surgical challenge. Many authors have reported a significant
incidence of unsatisfactory outcomes, especially in infancy,
because of the complexity of the CMV anatomy, the frequent
association with other heart defects, and a relative paucity of
patients within a wide spectrum of complex MV lesions.11-13
More recently, our group and others4-6,8 have reported
improved results, including lower postoperative morbidity
and mortality in patients undergoing MV surgery, with
a much reduced incidence of MV replacement.
In our current series CMV reconstruction rather than re-
placement proved feasible and successful in most patients.
Since January 1985, our surgical policy in the management
of CMV dysplasia has uniformly been a conservative one.
We are convinced that regardless of the anatomic and path-
ological severity of the valve dysplasia, CMV reconstructive
surgery should be attempted in any infant or child, with the
aim of avoiding the high incidence of early and late compli-
cations, as well as the high mortality and reoperation rates
related to prosthetic valve replacement in the pediatric age
group.14,15 Despite the fact that MV replacement has been
reported successfully even for more severe variants of
CMV anomalies for a long time,16 prosthetic CMV replace-
ment is still associated with persistent problems (eg, hemo-
lysis, perivalvular leak, prosthetic valve thrombosis,
thromboembolism, and endocarditis) and technical difficul-
ties (eg, the necessity of placing it in an extra-anatomic po-
sition within the supra-annular area, which is demonstrated
to have worse immediate and long-term results).14,15,18
MV repair preserves the subvalvular and chordal appara-
tus, keeping intact the normal left ventricular geometry and
function.17 In agreement with Kruithof and colleagues,19
atrioventricular valve development is a process continuing
into the first months of postnatal life. Thus MV surgery
should be deferred as long as the patient’s condition
permits clinical management to enhance the chances for
a more successful and satisfactory repair. This tendency
has been supported by Krishnan and associates,20 who
have recently reported that delay of surgical intervention un-
til the onset of severe symptoms in children with significant
MR does not increase the risk for long-term ventricular dys-
function.
Realistically, CMV surgical repair, when performed on
a severely malformed MV in infancy, remains a palliative
temporary treatment. The main aim of a conservative surgi-
cal approach in severe types of CMV dysplasia is to obtain
an improvement in MV function, which should ameliorateThe Journal of Thoracic and Carthe clinical status, deferring eventual MV replacement to
an older age.
In our current series perioperative mortality was 8% (7/
93). Since our series began in 1972, the overall mortality
rate reflects a wide time frame. Consequently, our analysis
has identified an increased risk factor (18- and 4.7-fold,
respectively) for early death and loss of sinus rhythm in
those patients who underwent surgical repair before 1984.
In addition, 5 of the 7 early deaths occurred before 1984,
in an era when preoperative diagnosis, surgical techniques,
and postoperative treatment were less developed. After
1984, only 2 children in the complex group with severe pre-
operative left ventricular dysfunction caused by left ventric-
ular endocardial fibroelastosis died early after repair.
Several authors have identified a major risk factor for peri-
operative mortality in the presence of associated intracardiac
lesions.6,21,22 This increased risk might be due to a more
complex anatomy or to the presence of a concomitant left
outflow tract obstruction, ventricular septal defect, or
impaired preoperative ventricular function. For this reason,
we have subdivided our population into isolated and
complex groups, with the purpose of understanding whether
the associated cardiac lesions were responsible for a worse
outcome. Interestingly, our analysis did not demonstrate an
increased risk in the complex group for early or late
mortality, need for early primary surgical intervention, and
reoperation on the MV. However, patients with complex
CMV did demonstrate a significantly higher risk for at least
1 negative outcome at follow-up. The association of CMV
disease with additional complex intracardiac lesions had a sig-
nificant effect on late quality of life and repeated hospitaliza-
tion. Nevertheless, the durability of CMV repair appeared
to be independent of the presence of associated cardiac
anomalies.
Almost half of our patients presented with prevalent MV
stenosis. Despite a recent report of better outcomes for ste-
notic MV in comparison with dysplastic regurgitant MV,8
our current experience confirms our previous findings4,5
indicating that the presence of MS (or prevalent MS) is
predictive of negative outcomes. In fact, the death rate in
patients with MS is almost 5 times higher than that of
patients with MR (P ¼ .021; OR, 4.698). The Kaplan–
Meier actuarial survival curve also shows a lower survival
rate for patients with prevalent MS. Stenosis is also
associated with a higher rate of early surgical intervention
(P ¼ .006; OR, 7.219).
Balloon MV dilation for MS has been recently reported by
McElhinney and coworkers.23 In their experience 28% of
patients treated with a primary balloon dilatation had
moderate-to-severe MR soon after the procedure secondary
to tears of the MV, disruption of chordal structures, and/or
partially flail MV leaflets, leading to an immediate 5% death
rate and a further 20% death rate at 1 year of follow-up.
Based on our experience, even though infants were in thediovascular Surgery c Volume 140, Number 6 1243
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believe that better early and long-term results can be
achieved with a conservative surgical treatment of CMV
during cardiac surgery that allows simultaneous repair of
the associated lesions.
In our experience prevalent MR has been slightly more
frequent when compared with MS, accounting for 51.6%
of our patients. Reconstructive surgery for MR can be
achieved by using the techniques described by Carpentier
and associates.9 Occasionally, in relieving a prevalent MV
stenosis, a better MV competence can also be achieved by
means of an improved leaflet coaptation. The use of a Car-
pentier ring has been advocated by many authors,7 so as to
achieve a proper CMV competence. We have used a ring an-
nuloplasty exclusively in our early experience. Our current
and previous results4,5 demonstrate the effectiveness of
a mural leaflet prosthetic-less annuloplasty favoring any
conservative procedure that avoids the use of prosthetic ma-
terial. Scar tissue caused by sutures and the ring itself might
limit proper annular growth and leaflet motion.4,5
This analysis has again shown that a parachute MV carries
a significant additional risk factor for early mortality and for
the need for reoperation. A recent report by Marino and
associates24 concerning surgical risks related to parachute
MV and conotruncal anomalies also supports our findings.
There are some limitations to this study, especially the ret-
rospective nature of the analysis. In addition, patients were
managed over a span of more than 30 years, during which
time nonanatomic factors influencing outcome might have
changed. However, despite this and the intrinsic palliative
nature of mitral repair in this age group, we strongly advise
conservative surgical intervention for any kind of MV dys-
plasia, especially in infants, to avoid the drawbacks of cur-
rently available prostheses and to improve quality of life
in these children.
In conclusion, surgical repair of MV dysplasia in infants
and children is an effective and reliable treatment with a de-
creasing early and late mortality and reoperation rate, even in
the most complex anatomic variants. MV reconstruction
needs to be carefully planned and tailored to each patient,
with the aim of achieving a ‘‘physiological’’ repair rather
than an ‘‘anatomic’’ one. Anatomic severity of MV malfor-
mations influences the long-term freedom from MV replace-
ment in both the isolated and complex groups. A ‘‘true’’
parachute MV adds a significant risk.
We thank Dr Aldo R. Castaneda for reviewing and improving
the value of the manuscript.
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